EDITORIAL SECTION

Articles

Clinical Trials: Failures and Challenges on the Path to Treating Alzheimer’s

Alzheimers disease AD is a neurodegenerative disorder with symptoms of memory loss and cognitive disability Typically it begins with mild symptoms that progress to become more severe AD is the th leading cause of death in the United States among people or older In million Americans suffered from AD and this is expected to rise to million by

From Molecule to Market: Building a Regulatory-Ready Manufacturing Strategy

Every pharmaceutical executive can recite the journey from molecule to market Far fewer can say with confidence at which point in that journey their manufacturing strategy became capable of withstanding a regulatory inspection The distinction matters more than it once did Approval timelines are compressing

Nanosizing: An Enthralling Strategy to Improve the Systemic Availability of Poorly Soluble Drugs

To enable the effective preclinical testing efficacy and safety evaluation followed by firstinman studies formulation scientists must come up with effective strategies to achieve the desired bioavailability of these poorly soluble compounds

Blockchain in Pharma: Strengthening Drug Traceability, Compliance, and Supply Chain Security

For most of the last decade the European pharmaceutical industry framed supply chain integrity as a packaging problem Put a unique identifier on every pack seal it with an antitampering device check it at the point of dispensing and the falsified medicine threat would be contained Since February that model has been law across the European Union and it has worked better than many sceptics predicte...

Adaptive Trial Designs: Enhancing Speed and Decision-Making in Clinical Development

For decades the traditional clinical trial has followed a rigid script A protocol is written patients are enrolled the study runs to completion and only at the very end does the sponsor learn whether the investment paid off The model has served the industry well in terms of scientific rigour

Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability

In an age where global environmental sustainability is imperative various industries are reassessing their practices to diminish their ecological impact The pharmaceutical sector a crucial component of healthcare is no different This article explores the proactive steps taken by pharmaceutical companies to incorporate sustainability into manufacturing packaging and operations to lessen their envir...

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys